nh kh nng chng oxy ha mnh, ng thi gip ci thin sc t da, tr li ln da khe mnh, v trng sng mn mng
76 This finding is of interest because for many common cancers, adding molecularly targeted agents to radiotherapy can increase preclinical cure rates, 79,80,81 and currently the only targeted agent clinically approved for this application is the EGFR antagonist, cetuximab
Bladder cancer drugs were one example suggested for exclusion as C-APC packaging of their product would be cost prohibitive
This was not the case for the medial frontal cortex nor when an analysis was done including all areas
Adding an additional 30 to 90 units of bacteriostatic water to the syringe before injection reduces local reaction significantly
Additionally, BPC 157 has shown promise in ameliorating neurological deficits after strokes in animal models, indicating a potential area for human clinical trials